(2021). Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country.
Chicago Style (17th ed.) CitationCost-utility of Omalizumab for the Treatment of Uncontrolled Moderate-to-severe Persistent Pediatric Allergic Asthma in a Middle-income Country. 2021.
MLA (8th ed.) CitationCost-utility of Omalizumab for the Treatment of Uncontrolled Moderate-to-severe Persistent Pediatric Allergic Asthma in a Middle-income Country. 2021.
Warning: These citations may not always be 100% accurate.